COSMOS Pharmaceutical Corporation (3349.T)

9053.0035.00 (-0.39%)

COSMOS Pharmaceutical Corporation (3349.T) stock comprehensive Cash Flow Analysis including operating cash flow, investing cash flow, financing cash flow, free cash flow, cash flow from operations, cash flow from investing, cash flow from financing. Compare cash flow against peers/competitors, industry and sector standards.

Low Bankruptcy RiskLow ProfitabilityEfficient OperationsModerate GrowthModerate QualityAdequate Dividend ProfileIndustry Rank: 67.57%Sector Rank: 75.68%

JPX - Healthcare - Medical - Pharmaceuticals | Market Cap: 717.52B | Next Earnings Date: 14 Oct 2025

Day's Range

8935.00 - 9125.00

52-Week Range

6347.00 - 10045.00

Volume

380.0K / 335.9K (Avg.)

P/E Ratio | EPS

23.15 | 391.09

Trending:

3349.T Cash Flow Analysis - Compare Against 9843.T

Comparison against 9843.T

None 3391.T 3141.T 3088.T 2127.T 9843.T

Reveals whether the business's core operations generate sufficient cash to cover expenses, fund growth, and return capital to shareholders. Sustainable free cash flow is often a key indicator of long-term value creation.

Operating Cash Flow per Share

-23.74

OCF/share of $3–5 – Solid range. Seth Klarman would ensure the company can fund growth and dividends internally.

Free Cash Flow per Share

-43.16

FCF/share $2–3 – Adequate. Seth Klarman might see if incremental growth can lift free cash flow further.

Capex-to-Operating Cash Flow

-81.81%

Negative ratio while 9843.T is 0.00%. Joel Greenblatt would question whether the firm’s OCF is negative or capex is abnormally large.

Income Quality Ratio (OCF / Net Income)

-0.74

Negative ratio while 9843.T is 0.00. Joel Greenblatt would check if we have far worse cash coverage of earnings.

Operating Cash Flow-to-Sales Ratio

-2.11%

OCF-to-sales 15–25% – Good. Seth Klarman would check if there is still room to optimize working capital.

Select Chart Metric: